Ensysce Biosciences, Inc.
ENSCEnsysce Biosciences, Inc. in brief
Ensysce Biosciences, Inc. is a listed company in the Biotechnology industry, based in La Jolla, California, USA. It was founded in 2003. Its market value was $10 M on 19 October 2026, which makes it the 25,841st largest listed company in the world and the 4,297th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $10 M. Its largest product and service lines by sales in 2025 were MPAR (100%). Its shares trade under the symbol ENSC (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Ensysce Biosciences, Inc.
The mailing address of our principal executive office is 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037. Our corporate telephone number is (858) 263-4196. Our website address is www.ensysce.com. Information contained on our website, or connected thereto, does not constitute part of, and is not incorporated by reference into, this Annual Report on Form 10-K.
Investors, the media, and others should note that we announce material information to the public through filings with the SEC, the investor relations page on our website, blog posts on our website, press releases, public conference calls, webcasts, and our X feed (@EnsysceBio).
From the company's annual report filed with the US SEC: read the report
Ensysce Biosciences, Inc. timeline
- 2003
- 🏁· approximateFounded
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering as Leisure Acquisition Corp.Final prospectus filed with the SEC on 1 December 2017; shares registered for exchange trading on 28 November 2017. The blank-check company later merged with the business that carries the name today.
- 2021
- ✎Renamed Ensysce Biosciences, Inc.Formerly Leisure Acquisition Corp..
- 2024
- 💰Record revenue of $5 millionFY2024, the highest of the 6 years on record.
Events of Ensysce Biosciences, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,436 (Jan 2022) · #5,759 (Dec 2022) · #5,575 (Jul 2023) · #4,656 (Jan 2024) · #2,486 (Mar 2026) · #4,099 (Aug 2026) · #4,237 (Oct 2026) · #4,299 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.6×
- Price / book
- 3.2×
- Free cash flow yield
- -78.4%
- Net margin (TTM)
- -1470.3%
- Operating margin
- -202.0%
- Return on equity
- -2835.2%
- Liabilities / assets
- 61.3%
- Revenue growth
- -2.7%
- R&D / revenue
- 204.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $5M | -2.7% | $-10M | $-10M | -200.8% |
| Dec 2024 | $5M | +133.6% | $-7M | $-8M | -153.4% |
| Dec 2023 | $2M | -11.5% | $-11M | $-11M | -476.7% |
| Dec 2022 | $3M | -28.6% | $-24M | $-24M | -960.7% |
| Dec 2021 | $4M | -10.2% | $-20M | $-29M | -825.8% |
| Dec 2020 | $4M | — | $-2M | $4M | 109.7% |
| Dec 2019 | — | — | $-3M | $-1M | — |
| Dec 2018 | — | — | $-1M | $2M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-8M | $0M | $-8M | $-3.98 | — |
| Dec 2024 | $-8M | — | — | $-11.45 | — |
| Dec 2023 | $-11M | — | — | $-70.40 | — |
| Dec 2022 | $-18M | — | — | $-139.42 | — |
| Dec 2021 | $-8M | — | — | $-1.48 | — |
| Dec 2020 | $-1M | — | — | $0.00 | — |
| Dec 2019 | $-1M | — | — | $-0.63 | — |
| Dec 2018 | $-1M | — | — | $-0.21 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $2M (+344.9% on a year earlier), net income $-82M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 2026DEF 14AProxy statement
- Nov 4, 20268-KCurrent reportDirectors or officers changed
- Oct 16, 20268-K/ACurrent report (amended)
- Sep 29, 20268-KCurrent reportBylaws amended
- Aug 25, 20268-KCurrent reportOther events
- Aug 24, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 6, 20268-K/ACurrent report (amended)
- Aug 6, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · Unregistered share sale · Directors or officers changed · Bylaws amended · Regulation FD disclosure
Official filings of Ensysce Biosciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $5 M
- Operating income
- $-10 M
- Net income
- $-10 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $5 M
- Total equity
- $3 M
As of December-2025
Top 19 institutional investors in Ensysce Biosciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners GP, L.L.C. | 9,471,711 | +9,322,000 (+6226.66%) | 48.68% | $4 M | Nov 16, 2026 |
| 2 | Jane Street Group, LLC | 466,084 | +257,251 (+123.19%) | 2.40% | $0 M | Nov 12, 2026 |
| 3 | Citadel Advisors LLC | 243,089 | +156,896 (+182.03%) | 1.25% | $0 M | Nov 16, 2026 |
| 4 | StoneX Group Inc. | 138,563 | New | 0.71% | $0 M | Nov 3, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 110,799 | New | 0.57% | $0 M | Nov 13, 2026 |
| 6 | Perceptive Advisors LLC | 86,666 | 0 (0.00%) | 0.45% | $0 M | Nov 16, 2026 |
| 7 | Geode Capital Management, LLC | 61,862 | -326 (-0.52%) | 0.32% | $0 M | Nov 6, 2026 |
| 8 | Virtu Financial LLC | 41,230 | -54,161 (-56.78%) | 0.21% | $0 M | Nov 17, 2026 |
| 9 | Renaissance Technologies LLC | 30,160 | New | 0.15% | $0 M | Nov 12, 2026 |
| 10 | XTX Topco Ltd | 19,110 | -57,895 (-75.18%) | 0.10% | $0 M | Nov 16, 2026 |
| 11 | Vanguard Capital Management LLC | 12,854 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 12 | Tower Research Capital LLC (TRC) | 6,081 | -13 (-0.21%) | 0.03% | $0 M | Nov 16, 2026 |
| 13 | FNY Investment Advisers, LLC | 3,000 | 0 (0.00%) | 0.02% | $0 M | Oct 16, 2026 |
| 14 | Robinhood Markets, Inc. | 2,949 | — | 0.02% | $0 M | Nov 18, 2026 |
| 15 | SBI Securities Co., Ltd. | 627 | -14 (-2.18%) | 0.00% | $0 M | Oct 22, 2026 |
| 16 | Citigroup Inc | 456 | New | 0.00% | $0 M | Nov 4, 2026 |
| 17 | Ascentis Independent Advisors | 80 | New | 0.00% | $0 M | Nov 3, 2026 |
| 18 | BlackRock, Inc. | 65 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 19 | UBS Group AG | 18 | New | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Ensysce Biosciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 72,454 | $0 M | 0.37% | <0.01% | +276% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 12,854 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Ensysce Biosciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Bob G. GowerDirector | Buy | +400,000 | $0.500 | $200 K | 916,740 | Form 4 |
| filed | Bob G. GowerDirector | Buy | +508,614 | $0.480 | $244 K | 516,740 | Form 4 |
| filed | Bob G. GowerDirector | Buy | +90,287 | $0.490 | $44 K | 1.22 M | Form 4 |
| filed | Bob G. GowerDirector | Buy | +270,000 | $0.480 | $130 K | 1.13 M | Form 4 |
| filed | Bob G. GowerDirector | Buy | +109,300 | $0.490 | $54 K | 862,395 | Form 4 |
| filed | Bob G. GowerDirector | Buy | +357,143 | $1.400 | $500 K | 753,095 | Form 4 |
| filed | Lynn KirkpatrickChief Executive Officer, Director | Buy | +27,000 | $0.530 | $14 K | 381,851 | Form 4 |
| filed | Lynn KirkpatrickChief Executive Officer, Director | Buy | +70,000 | $0.490 | $34 K | 354,851 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Ensysce Biosciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2020 | Q1 2020 | $136.3M |
Trading halts
- 2026-08-06 13:42 UTC, code LUDP, resumed 13:47 UTC
- 2024-12-16 17:04 UTC, code LUDP, resumed 17:09 UTC
- 2024-12-16 16:52 UTC, code LUDP, resumed 16:57 UTC
- 2024-12-16 16:23 UTC, code LUDP, resumed 16:28 UTC
- 2024-12-16 16:18 UTC, code LUDP, resumed 16:23 UTC
Fails to deliver
- : 16 shares at $0.52
- : 3,288 shares at $0.56
- : 102,019 shares at $0.56
- : 111,316 shares at $0.46
- : 10,464 shares at $0.43
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Ensysce Biosciences, Inc. scorecard#
Passes 5 of the 20 checks that could be worked out: strongest in growth (2 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 19, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-78.4%Free cash flow is -78.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 6
- ✗Revenue grew in the newest year-2.7%Revenue down 2.7% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years26.2%26.2% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median26.2%26.2% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-3.98 vs -11.45Diluted EPS -3.98 in fiscal 2025 against -11.45 the year before (report's currency).
- ✗Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against $4 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-202.0%-202.0% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-294.2%-294.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-202.0%-202.0% in fiscal 2025 against -961.1% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.6×Current ratio 1.59 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-28.35Z-score -28.35 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year266.3%Diluted shares up 266.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Ensysce Biosciences, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -202.0% | -60.5% | |
| Net margin | -200.8% | -68.9% | |
| Return on equity | -294.2% | -61.0% | |
| Revenue growth, 3 years a year | 26.2% | 12.9% | |
| Revenue growth | -2.7% | 15.8% | |
| Free cash flow margin | -156.4% | -61.5% |
2of 7on the Piotroski tests of financial strength
- Revenue fell 2.7% against the year before.
- Net loss of $10 million, the 5th loss-making year in a row.
- Free cash flow was negative: -$8 million.
- The share count rose 266.3% in the year.
Ensysce Biosciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 5.1−2.8%100% | 5.2+134%100% | 2.2−11.6%100% | 2.5−28.5%100% | 3.5−10.2%100% | 3.9—100% | — | — | |
| Research and development | 10+43.7%205% | 7.2−4.9%139% | 7.6−61.7%340% | 20+323%786% | 4.7+6.8%133% | 4.4—112% | — | — | |
| Selling, general and administrative | — | — | — | — | 19+1520%530% | 1.2—29.4% | — | — | |
| General and administrative | 4.9+4.4%97.3% | 4.7−11.9%90.6% | 5.4−22.4%240% | 6.9−63.1%274% | 19—530% | — | — | — | |
| Operating expenses | 15+28.2%302% | 12−7.8%229% | 13−51.6%581% | 27+14.3%1060% | 23+322%663% | 5.5r1.4+66.6%141% | 3.3+113%— | 1.6—— | |
| Operating income | −10—−202% | −6.7—−129% | −11—−481% | −24—−960% | −20—−563% | −1.6r−1.4—−41.0% | −3.3—— | −1.0—— | |
| Interest and finance income | — | — | — | — | — | 0.7−83.1%18.3% | 4.2+17.2%— | 3.6—— | |
| Interest expense and finance costs | 0.0−98.5%0.4% | 1.3+265%24.8% | 0.4+223%15.9% | 0.1−91.5%4.3% | 1.3+30.1%36.7% | 1.0—25.3% | — | — | |
| Provision for credit losses | — | — | −0.0—−0.0% | −0.0—−0.0% | −0.0−192%−0.1% | 0.0—0.0% | — | — | |
| Other non-operating income (expense) | 0.1—1.3% | −1.3−1467%−24.1% | 0.1+538%4.1% | 0.0—0.6% | −9.3−739%−263% | 1.5—36.9% | — | — | |
| Income before tax | — | — | — | — | — | 4.6r2.6—116% | −0.5r0.9−119%— | 2.7—— | |
| Income tax | — | — | — | — | — | 0.2−56.0%6.2% | 0.6+0.2%— | 0.6—— | |
| Net income including minority interests | −10—−201% | −8.0—−153% | −11—−476% | −24—−959% | −29—−825% | −0.2r0.0—−4.1% | −1.1r3.2−152%— | 2.1—— | |
| Minority interests' share of net income | −0.0—−0.0% | −0.0—−0.0% | −0.0—−0.6% | −0.0—−1.4% | −0.1—−1.8% | −0.2—−5.5% | — | — | |
| Net income attributable to shareholders | — | — | — | — | — | 4.3r2.4—110% | −1.1r0.4−150%— | 2.1—— | |
| Earnings per share, basic | -3.98—— | -11.45—— | -70.40r-4.69—— | -139.42r-11.62—— | -29.64r-1.48—— | 0.00r0.38—— | -0.63r-0.47—— | -0.21r-0.22—— | |
| Earnings per share, diluted | -3.98—— | -11.45—— | -70.40r-4.69—— | -139.42—— | -1.48—— | 0.00r0.38—— | -0.63r-0.47—— | -0.21r-0.22—— | |
| Shares, weighted average (basic) | 2.6+267%— | 0.7+362%— | 0.2r2.3−16.1%— | 0.2r2.2−82.2%— | 1.0r20−93.6%— | 16—— | — | — | |
| Shares, weighted average (diluted) | 2.6+267%— | 0.7+362%— | 0.2r2.3−16.1%— | 0.2−99.1%— | 20+22.2%— | 17r6.4+149%— | 6.6r6.1+0.4%— | 6.6r6.0—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 4.3+23.1%57.8% | 3.5+212%62.6% | 1.1−64.3%41.5% | 3.1−74.3%53.5% | 12+6215%74.7% | 0.2r0.0−81.7%55.2% | 1.1−36.0%0.5% | 1.7—0.8% | |
| Other current assets | 0.0r0.0+14.2%0.3% | 0.00.0%0.3% | 0.0−99.0%0.7% | 1.8—31.4% | — | — | — | — | |
| Current assets | 7.2r7.2+35.6%97.2% | 5.3+134%95.5% | 2.3−56.8%84.5% | 5.3−66.2%90.0% | 16+4402%95.4% | 0.3r0.2−71.0%98.9% | 1.2−37.4%0.6% | 1.9—0.9% | |
| Property, plant and equipment | 0.1—1.7% | — | — | — | — | 0.0—0.0% | — | — | |
| Right-of-use (leased) assets | — | — | — | — | — | 0.0—6.7% | — | — | |
| Total assets | 7.5+33.1%100% | 5.6+107%100% | 2.7−54.0%100% | 5.9−64.2%100% | 16+4567%100% | 0.4r13−99.8%100% | 197−4.1%100% | 205—100% | |
| Accounts payable | 3.3+141%43.8% | 1.4−29.9%24.2% | 1.9−34.2%71.5% | 2.9+878%50.0% | 0.3−82.5%1.8% | 1.7r0.3−37.8%490% | 2.8+546%1.4% | 0.4—0.2% | |
| Current liabilities | 4.6+107%61.3% | 2.2−33.8%39.4% | 3.3−64.8%123% | 9.5−42.6%161% | 16+135%100% | 7.0r0.3+153%1993% | 2.8r2.8+533%1.4% | 0.4—0.2% | |
| Non-current liabilities | — | 0.0−61.7%0.2% | 0.0−94.1%1.0% | 0.5−94.4%7.7% | 8.1—49.3% | — | — | — | |
| Total liabilities | 4.6+106%61.3% | 2.2−34.0%39.6% | 3.4−66.1%124% | 9.9−59.7%168% | 25+251%150% | 7.0r7.8−59.9%1993% | 18r10+32.9%8.9% | 13r7.4—6.4% | |
| Retained earnings | −140—−1875% | −130—−2314% | −122—−4489% | −111—−1885% | −86—−523% | −56r5.0—−15906% | −0.1r2.5−115%−0.1% | 0.9r2.1—0.5% | |
| Shareholders' equity | 3.2−13.3%43.1% | 3.7—66.3% | −0.3—−11.9% | −3.7—−63.1% | −7.9—−48.0% | −6.4r5.0−229%−1831% | 5.00.0%2.5% | 5.0—2.4% | |
| Minority interests | −0.3—−4.4% | −0.3—−5.9% | −0.3—−12.1% | −0.3—−5.4% | −0.3—−1.7% | −0.2—−61.9% | — | — | |
| Total equity | 2.9−14.7%38.7% | 3.4—60.4% | −0.7—−24.0% | −4.0—−68.5% | −8.2—−49.7% | −6.7—−1893% | −6.7—−3.4% | — | |
| Total liabilities and equity | 7.5+33.1%100% | 5.6+107%100% | 2.7−54.0%100% | 5.9−64.2%100% | 16+4567%100% | 0.4r13−99.8%100% | 197−4.1%100% | 205—100% | |
| Shares outstanding | 4.6+237%— | 1.4+546%— | 0.2r3.1−60.8%— | 0.5r6.4−56.6%— | 1.2r25−92.2%— | 16r6.2+123%— | 7.1r6.4+17.0%— | 6.0—— | |
| Cash-flow statement | |||||||||
| Share-based compensation | 0.2+59.9%3.5% | 0.1−87.4%2.1% | 0.9−18.0%39.4% | 1.1+780%42.5% | 0.1−31.9%3.4% | 0.2—4.5% | — | — | |
| Cash from operating activities | −7.8—−154% | −7.5—−144% | −11—−483% | −18—−709% | −8.2—−233% | −1.2r−0.9—−31.7% | −1.4—— | −1.2—— | |
| Capital expenditure | −0.1—−2.4% | — | — | — | — | — | — | — | |
| Cash from investing activities | −0.1—−2.4% | — | — | 0.0—0.2% | — | 183+1447%4665% | 12+1313%— | 0.8—— | |
| Debt issued | — | — | — | — | 16—450% | — | — | — | |
| Shares issued | — | — | — | — | 6.6—188% | −185—−4700% | −12—— | — | |
| Shares bought back | — | — | — | — | — | −185—−4700% | −12—— | — | |
| Cash from financing activities | 8.7−11.6%172% | 9.9+12.9%190% | 8.8−0.1%393% | 8.8−56.8%347% | 20+1747%575% | 1.1r−184—28.0% | −11—— | −0.0—— | |
| Change in cash | 0.8−66.0%16.0% | 2.4—45.7% | −2.0—−90.7% | −9.1−176%−361% | 12—342% | −0.1r−1.0—−3.7% | −0.6—— | −0.4—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 6.2+37.9%100% | 2.2+342%100% | 1.2−15.1%100% | 1.0−27.2%100% | 1.9*+44.4%100% | 0.5−85.6%100% | 1.4+654%100% | 1.3+332%100% | 1.3*+153%100% | 3.4—100% | 0.2—100% | 0.3—100% | 0.5*—100% | |
| Research and development | 13+19.3%204% | 3.2+7.5%146% | 2.5+28.5%212% | 3.3+77.5%348% | 3.6*−5.0%192% | 3.0+74.8%599% | 1.9+103%140% | 1.9+142%143% | 3.8*+70.3%292% | 1.7—49.5% | 0.9—521% | 0.8—255% | 2.2*—434% | |
| General and administrative | 5.1+2.7%82.3% | 1.6+24.7%73.1% | 1.3+5.9%109% | 1.2−16.1%122% | 1.1*−2.4%55.8% | 1.3+18.1%259% | 1.2+0.7%87.4% | 1.4+2.3%106% | 1.1*−25.1%82.7% | 1.1—31.7% | 1.2—655% | 1.4—448% | 1.4*—279% | |
| Operating expenses | 98+529%1577% | 85+1900%3881% | 3.7+19.8%321% | 4.5+37.6%471% | 4.7*−4.4%248% | 4.2+52.6%859% | 3.1+46.1%228% | 3.3+53.0%249% | 4.9*+32.9%374% | 2.8—81.1% | 2.1—1176% | 2.1—703% | 3.7*—713% | |
| Operating income | −91—−1477% | −82—−3781% | −2.6—−221% | −3.6—−371% | −2.8*—−148% | −3.7−680%−759% | −1.8—−128% | −2.0—−149% | −3.6*—−274% | 0.6—18.9% | −2.0—−1076% | −1.8—−603% | −3.2*—−613% | |
| Interest expense and finance costs | 0.0−47.1%0.2% | 0.0−50.6%0.1% | 0.0−89.9%0.0% | 0.0+1.7%0.4% | 0.0*−49.9%0.3% | 0.0+56.8%1.3% | 0.0−88.5%0.2% | 0.0−99.7%0.3% | 0.0*−96.9%0.8% | 0.0—0.1% | 0.0—15.2% | 1.2—408% | 0.3*—66.9% | |
| Provision for credit losses | — | — | — | — | — | — | — | — | — | — | — | — | −0.0*—−0.0% | |
| Other non-operating income (expense) | 0.4+548%6.6% | 0.4+3097%17.5% | 0.0−67.6%0.5% | 0.0−73.5%0.6% | 0.0*+14.9%0.7% | 0.0−29.7%2.4% | 0.0—1.2% | 0.0—1.7% | 0.0*—0.9% | 0.0—0.5% | −0.0—−6.8% | −1.3—−417% | −0.3*—−67.7% | |
| Net income including minority interests | −91—−1470% | −82—−3764% | −2.6—−221% | −3.6—−370% | −2.8*—−147% | −3.7−664%−756% | −1.7—−126% | −1.9—−147% | −3.6*—−273% | 0.7—19.4% | −2.0—−1082% | −3.1—−1019% | −3.5*—−680% | |
| Minority interests' share of net income | — | 0*—0.0% | −0.0—−0.0% | — | −0.0*—−0.0% | 0*—0.0% | −0.0—−0.0% | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −0.0—−0.0% | −0.0*—−0.2% | |
| Earnings per share, basic | — | -4.52—— | -0.20—— | -0.52—— | — | -1.29−229%— | -0.79—— | -1.39—— | — | 1.00r0.07—— | -3.35r-0.22—— | -8.21r-0.55—— | — | |
| Earnings per share, diluted | — | -4.52—— | -0.20—— | -0.52—— | — | -1.29−229%— | -0.79—— | -1.39—— | — | 1.00r0.07—— | -3.35r-0.22—— | -8.21r-0.55—— | — | |
| Shares, weighted average (basic) | 18+530%— | 18+530%— | 13+492%— | 6.8+388%— | — | 2.9+338%— | 2.2+275%— | 1.4+269%— | — | 0.7r9.9—— | 0.6r8.8—— | 0.4r5.7—— | — | |
| Shares, weighted average (diluted) | 18+530%— | 18+530%— | 13+492%— | 6.8+388%— | — | 2.9+338%— | 2.2+275%— | 1.4+269%— | — | 0.7r9.9—— | 0.6r8.8—— | 0.4r5.7—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 30—95.9% | 30+1673%95.9% | 0.7−69.4%22.9% | 0.7−75.6%34.4% | 4.3+23.1%57.8% | 1.7−59.7%52.6% | 2.2+112%39.7% | 3.1−10.3%66.2% | 3.5+212%62.6% | 4.2—44.3% | 1.0—37.3% | 3.4—67.1% | 1.1—41.5% | |
| Other current assets | 0.0—0.1% | 0.0−59.0%0.1% | 0.0−91.5%0.7% | 0.0−88.5%1.2% | 0.0r0.0+14.2%0.3% | 0.1+279%2.1% | 0.2+274%4.3% | 0.2+773%4.8% | 0.00.0%0.3% | 0.0—0.2% | 0.1—2.3% | 0.0—0.5% | 0.0—0.7% | |
| Current assets | 31—99.5% | 31+952%99.5% | 2.8−46.1%96.2% | 2.0−54.4%92.7% | 7.2r7.2+35.6%97.2% | 2.9−67.8%92.1% | 5.3+115%94.7% | 4.4−6.3%95.4% | 5.3+134%95.5% | 9.1—96.9% | 2.5—88.0% | 4.7—92.6% | 2.3—84.5% | |
| Property, plant and equipment | 0.2—0.5% | 0.2+26.4%0.5% | 0.1—3.8% | 0.1—5.4% | 0.1—1.7% | 0.1—3.9% | — | — | — | — | — | — | — | |
| Total assets | 31—100% | 31+874%100% | 3.0−46.9%100% | 2.2−53.0%100% | 7.5+33.1%100% | 3.2−66.1%100% | 5.6+99.4%100% | 4.6−9.1%100% | 5.6+107%100% | 9.4—100% | 2.8—100% | 5.1—100% | 2.7—100% | |
| Accounts payable | 2.0—6.6% | 2.0+339%6.6% | 2.0+89.6%66.9% | 1.6+162%74.3% | 3.3+141%43.8% | 0.5−76.4%14.6% | 1.0+116%18.7% | 0.6−37.3%13.3% | 1.4−29.9%24.2% | 2.0—21.0% | 0.5—17.2% | 1.0—19.3% | 1.9—71.5% | |
| Current liabilities | 3.8—12.4% | 3.8+66.7%12.4% | 4.1+61.9%138% | 2.8+61.1%131% | 4.6+107%61.3% | 2.3−17.7%72.5% | 2.5+92.3%45.1% | 1.8+7.6%38.2% | 2.2−33.8%39.4% | 2.8—29.9% | 1.3—46.7% | 1.6—32.2% | 3.3—123% | |
| Non-current liabilities | — | — | — | — | — | 0.0−98.9%0.0% | 0.0−89.3%0.0% | 0.1+647%2.8% | 0.0−61.7%0.2% | 0.0—0.0% | 0.0—0.3% | 0.0—0.3% | 0.0—1.0% | |
| Total liabilities | 3.8—12.4% | 3.8+66.7%12.4% | 4.1+61.8%138% | 2.8+50.0%131% | 4.6+106%61.3% | 2.3−17.8%72.5% | 2.5+91.0%45.1% | 1.9+14.4%41.0% | 2.2−34.0%39.6% | 2.8—29.9% | 1.3—47.1% | 1.7—32.6% | 3.4—124% | |
| Retained earnings | −228—−736% | −228—−736% | −146—−4932% | −143—−6609% | −140—−1875% | −137—−4307% | −133—−2390% | −131—−2851% | −130—−2314% | −126—−1342% | −127—−4530% | −125—−2457% | −122—−4489% | |
| Shareholders' equity | 27—88.7% | 27+2180%88.7% | −0.8−123%−26.4% | −0.3−111%−15.7% | 3.2−13.3%43.1% | 1.2−82.6%37.8% | 3.4+87.5%60.8% | 3.0−18.7%66.1% | 3.7—66.3% | 6.9—73.6% | 1.8—64.7% | 3.7—73.9% | −0.3—−11.9% | |
| Minority interests | −0.3—−1.1% | −0.3—−1.1% | −0.3—−11.1% | −0.3—−15.2% | −0.3—−4.4% | −0.3—−10.3% | −0.3—−5.9% | −0.3—−7.1% | −0.3—−5.9% | −0.3—−3.5% | −0.3—−11.7% | −0.3—−6.5% | −0.3—−12.1% | |
| Total equity | 27—87.6% | 27+3000%87.6% | −1.1−136%−37.6% | −0.7−125%−30.9% | 2.9−14.7%38.7% | 0.9−86.7%27.5% | 3.1+107%54.9% | 2.7−20.5%59.0% | 3.4—60.4% | 6.6—70.1% | 1.5—52.9% | 3.4—67.4% | −0.7—−24.0% | |
| Total liabilities and equity | 31—100% | 31+874%100% | 3.0−46.9%100% | 2.2−53.0%100% | 7.5+33.1%100% | 3.2−66.1%100% | 5.6+99.4%100% | 4.6−9.1%100% | 5.6+107%100% | 9.4—100% | 2.8—100% | 5.1—100% | 2.7—100% | |
| Shares outstanding | 19—— | 19+512%— | 16+578%— | 9.3+464%— | 4.6+237%— | 3.2−77.1%— | 2.4−70.6%— | 1.6−77.6%— | 1.4+546%— | 14—— | 8.2—— | 7.3—— | 0.2r3.1—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.0—0.6% | 0.0*—0.0% | 0.0*−99.0%0.2% | 0.0−46.2%0.9% | 0.0*−19.3%1.3% | — | 0.2r0.1*+603%13.6% | 0.0−51.1%1.2% | 0.0*−95.2%2.3% | 0.0*—0.6% | 0.0*—14.6% | 0.0—10.9% | 0.6*—122% | |
| Cash from operating activities | −8.4—−135% | −1.4*—−64.0% | −2.0*—−169% | −3.5—−364% | −1.5*—−81.1% | −1.9*—−378% | −2.7*—−197% | −1.7—−129% | −0.8*—−58.6% | −1.0*—−29.8% | −2.3*—−1271% | −3.4—−1115% | −1.8*—−350% | |
| Capital expenditure | — | — | — | — | 0*—0.0% | — | — | — | — | — | — | — | — | |
| Cash from investing activities | — | — | — | — | 0*—0.0% | — | — | — | — | — | — | — | — | |
| Shares issued | — | — | — | — | — | −0.4*—−81.1% | — | — | — | — | — | — | — | |
| Cash from financing activities | 25+438%408% | 19*+1225%882% | 1.9*+1.5%163% | −0.1−105%−6.7% | 4.2*+3598%221% | 1.5*−64.9%294% | 1.9*—136% | 1.3−77.9%95.3% | 0.1*−92.3%8.6% | 4.1*—121% | −0.1*—−28.2% | 5.7—1861% | 1.5*—284% | |
| Change in cash | 28—452% | 29*—1329% | −0.1*—−5.9% | −3.6—−371% | 2.6*—140% | −0.5*−117%−109% | −0.8*—−61.3% | −0.4−120%−34.1% | −0.7*—−50.0% | 3.1*—91.0% | −2.4*—−1299% | 2.3—746% | −0.3*—−66.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Ensysce Biosciences, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- MPAR$5 M100%+64%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Ensysce Biosciences, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Lynn Kirkpatrick | $487 K | $470 K | $394 K | $1 |
| 2024Dr. Lynn Kirkpatrick | $442 K | $442 K | $357 K | $6 |
| 2023Dr. Lynn Kirkpatrick | $509 K | $507 K | $417 K | $12 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Ensysce Biosciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 6 · Unregistered share sale 5 · Shareholder rights changed 1 · Bylaws or fiscal year changed 5 · Shareholder vote 1 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Bylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $77 M | Private placement after listing | $50 to $250 million | 44 | equity | SEC |
| Apr 2025 | $2 M | Private placement after listing | $2 to $10 million | 8 | options | SEC |
| Mar 2025 | $1 M | Private placement after listing | Under $2 million | 8 | options | SEC |
| Aug 2024 | $5 M | Private placement after listing | $2 to $10 million | 4 | options | SEC |
| Feb 2024 | $5 M | Private placement after listing | $2 to $10 million | 4 | options | SEC |
| Feb 2023 | $3 M | Private placement after listing | $2 to $10 million | 8 | options | SEC |
| Jun 2022 | $4 M | Private placement after listing | $2 to $10 million | 3 | debt, options | SEC |
| Sep 2021 | $5 M | Private placement after listing | $2 to $10 million | 3 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Ensysce Biosciences, Inc. compares in Biotechnology
- Market cap$10 M · higher than 11% of 726
- Revenue$5 M · higher than 36% of 647
- Revenue growth-2.7% · higher than 40% of 438
- Price / sales1.6× · lower than 88% of 339
- Price / book3.1× · lower than 47% of 534
- FCF yield-78.4% · higher than 14% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Ensysce Biosciences, Inc.🇺🇸 | $10 M | — | — | -2.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 19, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 19, 2026
Figures from Market data, SEC filing, Wikidata, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Ensysce Biosciences, Inc.? Verify and update this profile — free
Show Ensysce Biosciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.